Erythromycin News and Research

RSS

Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis. Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus.

Antibiotic resistance in dolphins mirrors disturbing trend in humans

Antibiotic resistance in bottlenose dolphins shows that up to 88% of pathogenic organisms in this species is resistant to one or more antibiotics. This finding offers very useful insights into the identical phenomenon in humans. This species is termed a sentinel species, which means it reflects environmental risks to humans in advance of their occurrence in humans.

16 Sep 2019

Thames typical of superbug-breeding rivers, says new study

The River Thames is rapidly becoming a breeding pool for antibiotic-resistant bacteria, according to a new study, which underlines the urgent need to cut down the amount of antibiotics currently being discharge into the river by at least 80% to arrest this trend.

5 Sep 2019

Women and older adults at increased risk of dangerous drug interactions

A new study led by researchers at Indiana University has found that women and older adults who use multiple prescription drugs are significantly more likely to be prescribed pills whose combination produces dangerous side effects.

12 Aug 2019

London's canals and ponds contain high levels of antibiotic-resistant genes

Central London's freshwater sources contain high levels of antibiotic resistant genes, with the River Thames having the highest amount, according to research by UCL.

26 Jul 2019

Antibiotic levels in water and potential risk of drug-resistant bugs

A JRC report brings together data on antibiotic levels in water, showing that small concentrations have found their way into a range of Europe's waterbodies.

27 Mar 2019

New approach helps clinicians to decide most effective antibiotic treatment courses

A scientific team from Case Western Reserve University School of Medicine and Cleveland Clinic has developed a new way to identify second-line antibiotics that may be effective in killing germs already resistant to a first-line antibiotic - potentially helping overcome antibiotic resistance.

31 Jan 2019

Drug development options diversified with new manganese catalyst

A University of Illinois team of researchers led by chemistry professor M. Christina White has developed a new manganese-based catalyst that can change the structure of druglike molecules to make new drugs, advancing the pace and efficiency of drug development.

9 Jan 2019

FDA expands approval of Vertex' cystic fibrosis medicine to treat children aged 12 to <24 months

Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

16 Aug 2018

Changes in bacterial environment may predict risk of preterm birth

A recent study has found that changes in microbial communities within the reproductive tract of pregnant women were strongly linked to premature birth.

26 Jan 2018

Changes in vaginal bacteria associated with premature births

Changes to the communities of microbes living in the reproductive tract of pregnant women could help to spot those at risk of giving birth prematurely.

24 Jan 2018

Study finds increasing susceptibility of Staphylococcus aureus in U.S. hospital patients

Findings from a study that looked at susceptibility trends of Staphylococcus aureus in U.S. hospital patients showed that key antibiotics used to treat the bacteria became more active over the course of the study, a rare occurrence.

5 Jun 2017

Swiss researchers discover potential way to design new antibiotics

Two Swiss research teams from the University of Bern and the ETH Zurich have developed a new method to shed light onto a mostly unknown process of bacterial protein production. Their results could be used for the design of new antibiotics.

10 May 2017

Researchers unravel how drug interacts with ribosome to halt protein production

The discovery of a chemical compound that halts the production of a small set of proteins while leaving general protein production untouched suggests a new drug search strategy: Find compounds that target undesired proteins before they are even made.

23 Mar 2017

Researchers find way to make changes to enzyme-driven assembly line to improve antibiotics

Researchers from North Carolina State University have discovered a way to make pinpoint changes to an enzyme-driven "assembly line" that will enable scientists to improve or change the properties of existing antibiotics as well as create designer compounds.

30 Nov 2016

Dirt beneath New York City may provide new weapons to fight against disease

Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.

29 Nov 2016

Harvard researchers create new, simplified platform for antibiotic discovery

Harvard researchers have created a new, greatly simplified, platform for antibiotic discovery that may go a long way to solving the crisis of antibiotic resistance.

23 May 2016

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

New TSRI discovery could open way to incorporate sulfur into natural antibiotic products

In a discovery with implications for future drug design, scientists from the Florida campus of The Scripps Research Institute have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.

11 Aug 2015

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015